Funds

Torax Medical receives a $30 million investment

Name Torax medical

Target The proceeds will be used to expand commercialization efforts for the company’s unique family of sphincter augmentation products

Investors Piper Jaffray Merchant Banking, Sanderling Ventures, Thomas Mcnerney & Partners, Accuitive Medical Ventures, Kaiser Permanente and Mayo Medical Ventures

FUND Torax medical secures $30m financing to commercialize pioneering treatment for reflux disease.

INVESTOR The $30 million Series D round of financing was led by Piper Jaffray Merchant Banking. Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures, Kaiser Permanente and Mayo Medical Ventures also participated.

TARGET The proceeds will be used to expand commercialization efforts for the company’s unique family of sphincter augmentation products. The company’s lead product, the LINX® Reflux Management System, is a surgical treatment of Gastroesophageal reflux disease (GERD). LINX was approved by the US Food and Drug Administration (FDA)

in March following a unanimous recommendation by an FDA advisory review panel.

PEOPLE Torax Medical, Inc. is a privately held medical device company headquartered in St. Paul, Minnesota that develops and markets products designed to treat chronic diseases related to defective sphincter muscles. The company’s technology platform, Magnetic Sphincter Augmentation (MSA), employs a small implant comprised of interlinked titanium beads with magnetic cores. The magnetic attraction between the beads augments the existing sphincter’s barrier function to prevent reflux or incontinence. The devices are implanted with standard minimally invasive laparoscopic or surgical procedures. The LINX Reflux Management System for the treatment of GERD is marketed in both the USA and in Europe and the FENIX™ Continence Restoration System for the treatment of Fecal incontinence (FI) is marketed in Europe.

Foundation Medicine receives a $42.5 million investment

FUND Foundation Medicine Announces $42.5 Million Series B Financing

INVESTOR In this round, public crossover funds Deerfield Management Company, L.P., Casdin Capital, Redmile Group and strategic investors Roche Venture Fund and WuXi Corporate Venture Fund joined founding investor Third Rock Ventures and current venture capital backers Google Ventures and Kleiner Perkins Caufield & Byers. One undisclosed fund and one undisclosed strategic investor also joined the round. Foundation Medicine’s board of directors remains unchanged.

TARGET The proceeds from the financing will help Foundation Medicine expand commercial operations, scale laboratory capabilities and develop additional genomic profiling and information services. FoundationOne™ is a genomic assay for all solid tumors that identifies oncogenic alterations in the tumor and provides a concise report to help physicians match patients with the targeted drugs or clinical trials that may be best suited for their unique cancer. Launched in June 2012, FoundationOne has already been ordered by more than 400 physicians from 16 countries.

Name Foundation Medicine

Target To expand commercial operations, scale laboratory capabilities and develop additional genomic profiling and information services.

Investors Third Rock Ventures, Google Ventures, Kleiner Perkins Caufield & Byers, Deerfield Management Company, L.P., Casdin Capital, Redmile Group, Roche Venture Fund and WuXi Coorporate Venture Fund

Virtual Instruments Raises $27.5 Million in Series D Funding

Name Virtual Instruments

Target invest in product development and expand its market presence.

Investors Next World Capital, General Catalyst Partners & Lightspeed Venture Partners

FUND Virtual Instruments, the leader in Infrastructure Performance Management (IPM) for physical, virtual and cloud computing environments, today announced $27.5 million in Series D funding.

INVESTOR The funding round was co-led by Next World Capital and General Catalyst Partners with continued participation from existing investor Lightspeed Venture Partners.

TARGET Virtual Instruments will use the funding to invest in product development and expand its market presence.

PEOPLE Virtual Instruments is a leader in Infrastructure Performance Management for physical, virtual and cloud computing environments. The award-winning VirtualWisdom® platform provides visibility into real-time performance and health of the entire open systems stack along with metrics that assess utilization. Virtual Instruments improves the performance and availability of mission-critical applications while lowering the cost of the supporting infrastructure. Forbes Magazine recognized the company as #6 on its 2011 list of America's Most Promising Companies. Virtual Instruments investors include General Catalyst Partners, Lightspeed Venture Partners, Next World Capital and Riverwood Capital. The company was founded in June 2008 via a spin-out from Finisar Corp.; it has headquarters in San Jose, Calif., and can be found online at http://www.virtualinstruments.com.